Publications
List of Publications
Meiring SM, Webb M, Goedhals D, Louw V (2012). HIV associated Thrombotic Thrombocytopenic Purpura – What we know so far. European Oncology and Haematology, 8(2):89-91.
Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk D (2012). Differential sensitivity of Von Willebrand factor (VWF) “activity” assays to large and small molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. Journal of Thrombosis and Haemostasis 10(6): 1043-1054.
Malan N, Von Kanel R, Schutte A, Huisman H. Smith W, Mels C, Kruger K, Meiring M, Van Rooyen J, Malan L (2013). Testosterone and acute stress are associated with fibrinogen and von Willebrand factor in African men: The SABPA study. International Journal of Cardiology 168 (5): 4638-4642.
Area(s) of Interest
I see myself as the go to person for Von Willebrand disease research and diagnosis in South Africa. I also enjoy international recognition by the Von Willebrand factor multimeric analysis assay that used by the RCPA are used forquality assurance programs. I was also invited to discuss the status of diagnosis of Von Willebrand disease in South Africa. I published in collaboration with Prof. Emmanuel Favaloro of the RCPA on several issues regarding Von Willebrand disease. My research on the role of Von Willebrand factor in haemostatic disorders has lead to collaborations with international and national laboratories. We found that Von Willebrand factor plays a major role in the pathogenesis of hypertension and stoke,
My research laid the foundation for innovative development of diagnostic assays. I am the inventor of a South African patent and two provisional international applications. I developed cost-effective assays to diagnose thrombotic thrombocytopaenic purpura (TTP), a thrombotic disorder and Von Willebrand disease (VWD), a bleeding disorder. The test measures the levels of ADAMTS-13, a protein that plays a crtical role in for TTP. The VWF-propeptide assay measures the increased clearance of the VWF molecule. We use it to determine the half-life of VWF in plasma. Patients with increased VWF clearance probably require alternative treatment strategies than those with normal VWF clearance. The current commercially available assays have only been available for the past two years and are still very expensive and the antibodies used in these assays are produced in animals. We produce antibodies using phage display technology. These highly specialized diagnostic assays are now done in South Africa at a fraction of the cost of commercially available assays.
Community Service
Service delivery:
My Special Haemostasis laboratory is the only one in South Africa that do all the diagnostic tests needed to accurately diagnose VWF, the most common bleeding disorder in South Africa for both the state and private laboratories. The laboratory is the only reference laboratory for VWD in the country.
More recently, I expanded the VWD reference center to a Special Haemostasis Testing Facility and concluded a service level agreement between the University of the Free State and the National Health Laboratory Service (NHLS) to increase our diagnostic capability.
Economic and Management Sciences
Education
Health Sciences
The Humanities
Law
Natural and Agricultural Sciences
Open Distance Learning
Theology and Religion
Business School
We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.